Since then, numerous clinical trials have evaluated the role of CD30-directed CAR-T, primarily for the treatment of classical Hodgkin lymphoma but also ALCL and other T-cell lymphomas in ongoing clinical trials. The gene discussed is TNFRSF8; the disease is Hodgkins lymphoma.